TFF2 and obesity due to melanocortin 4 receptor deficiency: The ultimate goal is to develop a novel generation of treatments and therapeutic targets for obesity and metabolic disorders that would pharmacologically target TFF2 pathways to mimic the antiobesity effects of Tff2 KO (Figure 2).